Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option.
Plasma proteomics study unlocks predictive biomarkers for TNBC immunotherapy
- Post author:admin
- Post published:
- Post category:uncategorized